Hypogonadism among Type 2 Diabetes Mellitus Patients with Male Erectile Dysfunction

Abstract Introduction  Testosterone levels and erectile function are known to decline as men age, leading to hypogonadism and erectile failure. Men with type 2 diabetes mellitus (T2DM) have a high prevalence of hypogonadism and erectile dysfunction. We aimed to estimate the prevalence of hypogonadism in T2DM patients complaining of erectile dysfunction. Patients and Methods  A cross-sectional study was conducted at Specialized Diabetes, Endocrine, and Metabolism Center from early September 2021 to the end of January 2022. The study included 115 fully anonymized randomly selected patients. Patients with diabetes were assessed for erectile dysfunction through a questionnaire derived from “The International Index of Erectile Function (IIEF).” Additionally, hypogonadism has been diagnosed with serum testosterone levels lower than 264 mg/dL according to the Endocrine Society 2018 criteria for the diagnosis of male hypogonadism. Results  The average duration of diabetes was 6.2 years, and the mean glycated hemoglobin value was 9.3%. Dyslipidemia was the most prevalent chronic comorbid condition (84.3%) accompanying diabetes and erectile dysfunction, followed by hypertension (56.5%). An approximately similar rate of hypogonadism was observed in patients with diabetes and erectile dysfunction regardless of whether the other chronic disease was also present. From 115 patients included in this study, hypogonadism was diagnosed in 26% of patients with diabetes and erectile dysfunction. Conclusion  A significant number of hypogonadisms occur in patients with diabetes and erectile dysfunction, which require particular emphasis.